Lundbeck posts rise in fourth-quarter sales, profit

Lundbeck announced Wednesday that fourth-quarter sales reached 4.4 billion Danish kroner ($729 million), up from 4.2 billion kroner ($696 million) in the year-ago period, with growth primarily driven by Brintellix/Trintellix, Northera, Onfi and Rexulti. Profit in the quarter was 553 million kroner ($92 million), higher than the 473 million kroner ($78 million) recorded in the same period of 2016. 

Regarding individual products, sales of Onfi climbed 27 percent versus the year-ago period to 807 million kroner ($133 million), while revenue from Brintellix/Trintellix jumped 41 percent to 467 million kroner ($77 million). Additionally, sales of Northera rose by 46 percent to 456 million kroner ($75 million), with revenue from Rexulti increasing by 24 percent to 336 million kroner ($55 million). 

In the quarter, sales in North America totalled 2.8 billion kroner ($462 million), reflecting growth of 9 percent. Meanwhile, revenue in international markets declined 11 percent to 731 million kroner ($121 million), with European sales falling 3 percent to 688 million kroner ($114 million). 

Chief financial officer Anders Götzsche said "2017 has been a successful financial year for Lundbeck as we grew the business and increased…profitability significantly." For 2017, sales rose 10 percent to 17.2 billion kroner ($2.9 billion), while profit reached 2.6 billion kroner ($431 million), up from 1.2 billion kroner ($199 million) a year earlier. 

"Going forward we will continue to focus on profitability, while at the same time focus on strengthening our pipeline to create long-term, sustainable and profitable growth," Götzsche remarked. For the current year, Lundbeck said it expects revenue of between 17.2 billion kroner ($2.9 billion) and 18 billion kroner ($3 billion), with earnings in the range of 4.8 billion kroner ($796 million) to 5.2 billion kroner ($862 million). Analysts estimate annual sales of around 17.9 billion kroner ($3 billion) on earnings of 4.85 billion kroner ($804 million).

Meanwhile, the drugmaker is seeking to replace former CEO Kare Schultz, who left for the same position at Teva last September. 


To read more Top Story articles, click here.